Compare ResMed Inc. (RMD) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Snowflake Inc — how do they compare? ResMed Inc. trades at $230.96 (market cap $31.89B), while Snowflake Inc trades at $365.21 (market cap $121.15B). The key difference: Snowflake Inc is far larger — about 3.8× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| RMD | SNOW | |
|---|---|---|
Market Cap | $31.89B | $121.15B |
Volume | 618,314 | 3,986,549 |
Sector | Health | Technology |
52-Week High | $277.88 | $356.47 |
52-Week Low | $182.82 | $121.11 |
Typical Hold Time | 51 Days | — |
Enterprise Value | $31.24B | $121.57B |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Snowflake (SNOW) trades at $360.12, up 8.19% in the past 24 hours, with strong technical momentum and bullish moving average signals. The company continues to show impressive revenue growth, reaching $3.63 billion in 2025, though it remains unprofitable with a net loss of $1.29 billion. Recent developments include a $3.75 billion convertible note offering and expanded partnerships with UiPath, while analysts maintain strong buy sentiment with an $418.03 consensus price target.
Snowflake presents a growth investment opportunity with accelerating revenue expansion and positive earnings beats, but faces significant execution risk due to persistent losses and high valuation multiples. The stock's 81% analyst buy rating reflects confidence in the company's AI data cloud positioning, though investors must weigh the premium valuation against ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
